Understanding how tau protein affects brain degeneration in Alzheimer's and Down Syndrome.
Cell and Network Disruptions and Associated Pathogenenesis in Tauopathy and Down Syndrome
This study is looking at how a protein called tau spreads in the brain and how it affects brain activity in people with Alzheimer's Disease and Down Syndrome, with the hope that understanding these processes can help find better treatments for cognitive decline.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10814964 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which tau protein transmission and increased neuronal activity contribute to neurodegeneration in Alzheimer's Disease and related conditions, including Down Syndrome. The study focuses on how tau spreads between neurons and how this process may be influenced by the overexpression of amyloid precursor protein due to Down Syndrome. By employing a multidisciplinary approach, researchers aim to uncover the intricate interactions within brain circuitry that lead to cognitive decline. Patients may benefit from insights that could inform future treatments targeting these pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's Disease or Down Syndrome, particularly those experiencing cognitive decline.
Not a fit: Patients with neurodegenerative conditions unrelated to tau pathology or those without cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for slowing or preventing neurodegeneration in Alzheimer's Disease and Down Syndrome.
How similar studies have performed: Previous research has shown promising results in understanding tau pathology and its role in neurodegeneration, suggesting that this approach could yield valuable insights.
Where this research is happening
San Francisco, United States
- J. David Gladstone Institutes — San Francisco, United States (Active)
Researchers
- Principal investigator: Finkbeiner, Steven M — J. David Gladstone Institutes
- Study coordinator: Finkbeiner, Steven M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.